MedTrace Logo

The Comparison of Ibandronate and Zoledronic Acid After Denosumab Discontinuation

NCT07406685 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2026-02-12

No results posted yet for this study

Summary

This study is a prospective, multicenter, open-label, randomized non-inferiority trial comparing intravenous ibandronate and zoledronic acid as sequential therapy after denosumab discontinuation in postmenopausal women with osteoporosis. This trial primarily targets patients with short-term denosumab exposure (less than three years) and is conducted as a preliminary investigation. The findings are expected to provide foundational evidence to inform the design of future studies assessing sequential therapies following longer-term denosumab treatment.

Conditions

  • Postmenopausal Osteoporosis
  • Postmenopausal Osteopenia
  • Primary Osteoporosis
  • Osteoporosis

Interventions

DRUG

Ibandronate IV

Ibandronate 3mg/3months for 12 months

DRUG

Zoledronic acid IV

Zoledronic acid 5mg/1year for 12 months

Sponsors & Collaborators

  • National Taiwan University

    collaborator OTHER

  • National Taiwan University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-17
Primary Completion
2030-03-17
Completion
2030-09-17

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07406685 on ClinicalTrials.gov